Top

Published in:

01-04-2019 | Glioblastoma | Clinical Study

Race influences survival in glioblastoma patients with KPS ≥ 80 and associates with genetic markers of retinoic acid metabolism

Authors: Meijing Wu, Jason Miska, Ting Xiao, Peng Zhang, J. Robert Kane, Irina V. Balyasnikova, James P. Chandler, Craig M. Horbinski, Maciej S. Lesniak

Published in: Journal of Neuro-Oncology | Issue 2/2019

Abstract

Purpose

To study whether the clinical outcome and molecular biology of gliomas in African-American patients fundamentally differ from those occurring in Whites.

Methods

The clinical information and molecular profiles (including gene expression array, non-silent somatic mutation, DNA methylation and protein expression) were downloaded from The Cancer genome atlas (TCGA). Electronic medical records were abstracted from Northwestern Medicine Enterprise Data Warehouse (NMEDW) for analysis as well. Grade II–IV Glioma patients were all included.

Results

931 Whites and 64 African-American glioma patients from TCGA were analyzed. African-American with Karnofsky performance score (KPS) ≥ 80 have significantly lower risk of death than similar white Grade IV Glioblastoma (GBM) patients [HR (95% CI) = 0.47 (0.23, 0.98), P = 0.0444, C-index = 0.68]. Therefore, we further compared gene expression profiles between African-American GBM patients and Whites with KPS ≥ 80. Extrapolation of genes significantly associated with increased African-American patient survival revealed a set of 13 genes with a possible role in this association, including elevated expression of genes previously identified as increased in African-American breast and colon cancer patients (e.g. CRYBB2). Furthermore, gene set enrichment analysis revealed retinoic acid (RA) metabolism as a pathway significantly upregulated in African-American GBM patients who survive longer than Whites (Z-score = − 2.10, Adjusted P-value = 0.0449).

Conclusions

African Americans have prolonged survival with glioma which is influenced only by initial KPS score. Genes previously associated with both racial disparities in cancer and pathways associated with RA metabolism may play an important role in glioma etiology. In the future exploration of these genes and pathways may inform novel therapies for this incurable disease.

Available only for authorised users

Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372(26):2481–2498. https://doi.org/10.1056/NEJMoa1402121 CrossRef

Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS (2018) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol. 20(suppl_4):iv1–iv86. https://doi.org/10.1093/neuonc/noy131 CrossRef

Barnholtz-Sloan JS, Maldonado JL, Williams VL, Curry WT, Rodkey EA, Barker FG, Sloan AE (2007) Racial/ethnic differences in survival among elderly patients with a primary glioblastoma. J Neuro-Oncol 85(2):171–180. https://doi.org/10.1007/s11060-007-9405-4 CrossRef

Barnholtz-Sloan JS, Sloan AE, Schwartz AG (2003) Racial differences in survival after diagnosis with primary malignant brain tumor. Cancer 98(3):603–609. https://doi.org/10.1002/cnr.11534 CrossRefPubMed

Barnholtz-Sloan JS, Sloan AE, Schwartz AG (2003) Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973–1997. J Neurosurg 99(3):458–466. https://doi.org/10.3171/jns.2003.99.3.0458 CrossRefPubMed

Keenan T, Moy B, Mroz EA, Ross K, Niemierko A, Rocco JW, Isakoff S, Ellisen LW, Bardia A (2015) Comparison of the genomic landscape between primary breast cancer in African American versus white women and the association of racial differences with tumor recurrence. J Clin Oncol 33(31):3621. https://doi.org/10.1200/Jco.2015.62.2126 CrossRefPubMedPubMedCentral

Harrell FE Jr (2001) Regression modelling strategies: With applications to linear models, logistic regression, and survival analysis. Springer, New YorkCrossRef

Heitjan DF, Little RJA (1991) Multiple imputation for the fatal accident reporting system. Appl Stat 40(1):13–29. https://doi.org/10.2307/2347902 CrossRef

Schenker N, Taylor JMG (1996) Partially parametric techniques for multiple imputation. Comput Stat Data Anal 22(4):425–446. https://doi.org/10.1016/0167-9473(95)00057-7 CrossRef

Newson RB (2010) Comparing the predictive powers of survival models using Harrell’s c or Somers’ D. Stata J 10(3):339–358CrossRef

10.

Cai J, Zhang W, Yang P, Wang Y, Li M, Zhang C, Wang Z, Hu H, Liu Y, Li Q, Wen J, Sun B, Wang X, Jiang T, Jiang C (2015) Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance. PLoS ONE 10(5):e0126022. https://doi.org/10.1371/journal.pone.0126022 CrossRefPubMedPubMedCentral

11.

Park CK, Lee SH, Han JH, Kim CY, Kim DW, Paek SH, Kim DG, Heo DS, Kim IH, Jung HW (2009) Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy. BMC Cancer 9:450. https://doi.org/10.1186/1471-2407-9-450 CrossRefPubMedPubMedCentral

12.

Gaujoux R, Seoighe C (2010) A flexible R package for nonnegative matrix factorization. BMC Bioinform 11:367. https://doi.org/10.1186/1471-2105-11-367 CrossRef

13.

Robertson JT, Gunter BC, Somes GW (2002) Racial differences in the incidence of gliomas: a retrospective study from Memphis, Tennessee. Br J Neurosurg 16(6):562–566CrossRefPubMed

14.

Wrensch M, Minn Y, Chew T, Bondy M, Berger MS (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 4(4):278–299CrossRefPubMedPubMedCentral

15.

Deorah S, Lynch CF, Sibenaller ZA, Ryken TC (2006) Trends in brain cancer incidence and survival in the United States: surveillance, epidemiology, and end results program, 1973 to 2001. Neurosurg Focus 20(4):E1. https://doi.org/10.3171/foc.2006.20.4.E1 CrossRefPubMed

16.

Xu H, Chen J, Qin Z (2017) Geographic variations in the incidence of glioblastoma and prognostic factors predictive of overall survival in US adults from 2004 to 2013. Front Aging Neurosci 9:352CrossRefPubMedPubMedCentral

17.

Gittleman H, Lim D, Kattan MW (2016) An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma:NRG Oncology RTOG 0525 and 0825. Neuro Oncol 19(5):669–677PubMedCentral

18.

19.

Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS (2018) Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol 4(9):1254–1262. https://doi.org/10.1001/jamaoncol.2018 CrossRefPubMedPubMedCentral

20.

Carson K, Grossman SA, Fisher JD, Shaw E (2005) Prognostic factors for survival in adult patients with recurrent glioma enrolled on new approaches to brain tumor therapy (NABTT) CNS consortium phase I and II clinical trials. J Clin Oncol 23(16):116s

21.

West HJ, Jin JO (2015) JAMA oncology patient page. Performance status in patients with cancer. JAMA Oncol 1(7):998. https://doi.org/10.1001/jamaoncol.2015.3113 CrossRefPubMed

22.

Curry WT Jr, Barker FG 2nd (2009) Racial, ethnic and socioeconomic disparities in the treatment of brain tumors. J Neurooncol 93(1):25–39. https://doi.org/10.1007/s11060-009-9840-5 CrossRefPubMed

23.

Thatcher JE, Isoherranen N (2009) The role of CYP26 enzymes in retinoic acid clearance. Expert Opin Drug Metab Toxicol 5(8):875–886. https://doi.org/10.1517/17425250903032681 CrossRefPubMedPubMedCentral

24.

Campos B, Centner FS, Bermejo JL, Ali R, Dorsch K, Wan F, Felsberg J, Ahmadi R, Grabe N, Reifenberger G, Unterberg A, Burhenne J, Herold-Mende C (2011) Aberrant expression of retinoic acid signaling molecules influences patient survival in astrocytic gliomas. Am J Pathol 178(5):1953–1964. https://doi.org/10.1016/j.ajpath.2011.01.051 CrossRefPubMedPubMedCentral

25.

Epping MT, Wang LM, Edel MJ, Carlee L, Hernandez M, Bernards R (2005) The human tumor antigen repressor of retinoic acid PRAME is a dominant receptor signaling. Cell 122(6):835–847. https://doi.org/10.1016/j.cell.2005.07.003 CrossRefPubMed

26.

Sun ZW, Wu ZP, Zhang FL, Guo QF, Li L, Li K, Chen H, Zhao J, Song DW, Huang Q, Li L, Xiao JR (2016) PRAME is critical for breast cancer growth and metastasis abs. Gene 594(1):160–164. https://doi.org/10.1016/j.gene.2016.09.016 CrossRefPubMed

27.

Xu Y, Yue QC, Wei H, Pan GJ (2015) PRAME induces apoptosis and inhibits proliferation of leukemic cells in vitro and in vivo. Int J Clin Exp Pathol 8(11):14549–14555PubMedPubMedCentral

28.

Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B (2002) Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogen 133(2):118–123. https://doi.org/10.1016/S0165-4608(01)00570-2 CrossRef

30.

Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M (2004) The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 10(13):4307–4313. https://doi.org/10.1158/1078-0432.Ccr-03-0813 CrossRefPubMed

31.

Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R (2008) PRAME expression and clinical outcome of breast cancer. Br J Cancer 99(3):398–403. https://doi.org/10.1038/sj.bjc.6604494 CrossRefPubMedPubMedCentral

32.

Weber JS, Vogelzang NJ, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL, Miles S, Rosario D, Diamond DC, Qiu Z, Obrocea M, Bot A (2011) A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother 34(7):556–567. https://doi.org/10.1097/CJI.0b013e3182280db1 CrossRefPubMedPubMedCentral

33.

Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291(22):2720–2726. https://doi.org/10.1001/jama.291.22.2720 CrossRefPubMed

34.

Chen MS Jr, Lara PN, Dang JH, Paterniti DA, Kelly K (2014) Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials. Cancer 120(Suppl 7):1091–1096. https://doi.org/10.1002/cncr.28575 CrossRefPubMedPubMedCentral

Title: Race influences survival in glioblastoma patients with KPS ≥ 80 and associates with genetic markers of retinoic acid metabolism
Authors: Meijing Wu
Jason Miska
Ting Xiao
Peng Zhang
J. Robert Kane
Irina V. Balyasnikova
James P. Chandler
Craig M. Horbinski
Maciej S. Lesniak
Publication date: 01-04-2019
Publisher: Springer US
Keywords: Glioblastoma
Glioma
Glioma
Glioblastoma
Glioblastoma
Glioma
Published in: Journal of Neuro-Oncology / Issue 2/2019
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-019-03110-5

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Race influences survival in glioblastoma patients with KPS ≥ 80 and associates with genetic markers of retinoic acid metabolism

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2019

Adaptation of visual cortex to damage of visual pathways in suprasellar tumors before and after gamma knife radiosurgery

Correction to: Clinical features, radiological profiles, and surgical outcomes of primary intracranial solitary plasmacytomas: a report of 17 cases and a pooled analysis of individual patient data

Supratentorial high-grade astrocytoma with leptomeningeal spread to the fourth ventricle: a lethal dissemination with dismal prognosis

MicroRNA regulating stanniocalcin-1 is a metastasis and dissemination promoting factor in glioblastoma

A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia

Effect of health disparities on overall survival of patients with glioblastoma